Evidence map›Paper›PMID 35008232›Full record

ArticleCancers2021

Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer.

Sami-Alexander Safi, Lena Haeberle, Alexander Rehders, Stephen Fung, Sascha Vaghiri, Christoph Roderburg, Tom Luedde, Farid Ziayee, Irene Esposito, Georg Fluegen and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05895214 (MESOPANC-01 Study), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05895214 not yet recruitingnot on this mapstarted 2023, after this paper: background citation

MESOPANC-01 Study: The Mesopancreas and the Ductal Adenocarcinoma of the Pancreatic Head: From Preoperative Imaging to Histopathological and Surgical Outcome

Typeobservational_patient_registrySponsorHeinrich-Heine University, DuesseldorfRan2023 to 2027Enrolled500ConditionsPDAC, Pancreatoduodenectomy, Margin, Resection, SurgeryArmsoncological relevance of the mesopancreas
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Sami-Alexander SafiDepartment of General, Visceral, Thoracic and Pediatric Surgery (A), Medical Faculty, Heinrich-Heine-University, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.ORCID 0000-0002-9874-9225
Lena HaeberleInstitute of Pathology, Medical Faculty, Heinrich-Heine-University, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Alexander RehdersDepartment of General, Visceral, Thoracic and Pediatric Surgery (A), Medical Faculty, Heinrich-Heine-University, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Stephen FungDepartment of General, Visceral, Thoracic and Pediatric Surgery (A), Medical Faculty, Heinrich-Heine-University, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.ORCID 0000-0002-7341-5798
Sascha VaghiriDepartment of General, Visceral, Thoracic and Pediatric Surgery (A), Medical Faculty, Heinrich-Heine-University, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Christoph RoderburgDepartment of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty, Heinrich-Heine-University, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Tom LueddeDepartment of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty, Heinrich-Heine-University, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Farid ZiayeeDepartment of Diagnostic and Interventional Radiology, Medical Faculty, Heinrich-Heine-University, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.ORCID 0000-0002-0247-8265
Irene EspositoInstitute of Pathology, Medical Faculty, Heinrich-Heine-University, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.ORCID 0000-0002-0554-2402
Georg FluegenDepartment of General, Visceral, Thoracic and Pediatric Surgery (A), Medical Faculty, Heinrich-Heine-University, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.ORCID 0000-0002-9322-1659
Wolfram Trudo KnoefelDepartment of General, Visceral, Thoracic and Pediatric Surgery (A), Medical Faculty, Heinrich-Heine-University, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Düsseldorf University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurvival following surgical treatment of ductal adenocarcinoma of the pancreas (PDAC) remains poor. The recent implementation of the circumferential resection margin (CRM) into standard histopathological evaluation lead to a significant reduction in R0 rates. Mesopancreatic fat infiltration is present in ~80% of PDAC patients at the time of primary surgery and recently, mesopancreatic excision (MPE) was correlated to complete resection. To attain an even higher rate of R0(CRM-) resections in the future, neoadjuvant therapy in patients with a progressive disease seems a promising tool. We analyzed radiographic and histopathological treatment response and mesopancreatic tumor infiltration in patients who received neoadjuvant therapy prior to MPE. The aim of our study was to evaluate the need for MPE following neoadjuvant therapy and if multi-detector computed tomographically (MDCT) evaluated treatment response correlates with mesopancreatic (MP) infiltration.

methodRadiographic, clinicopathological and survival parameters of 27 consecutive patients who underwent neoadjuvant therapy prior to MPE were evaluated. The mesopancreatic fat tissue was histopathologically analyzed and the 1 mm-rule (CRM) was applied.

resultsIn the study collective, both the rate of R0 resection R0(CRM-) and the rate of mesopancreatic fat infiltration was 62.9%. Patients with MP infiltration showed a lower tumor response. Surgical resection status was dependent on MP infiltration and tumor response status. Patients with MDCT-predicted tumor response were less prone to MP infiltration. When compared to patients after upfront surgery, MP infiltration and local recurrence rate was significantly lower after neoadjuvant treatment.

conclusionMPE remains warranted after neoadjuvant therapy. Mesopancreatic fat invasion was still evident in the majority of our patients following neoadjuvant treatment. MDCT-predicted tumor response did not exclude mesopancreatic fat infiltration.

Indexed as

CRMmesopancreasmesopancreatic excisionneoadjuvantPDACperipancreatic tissue

Identifiers

PMID35008232
PMCPMC8750596
OpenAlexW4200407790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.